Skip Navigation


Carcinogenesis Advance Access originally published online on October 7, 2004
Carcinogenesis 2005 26(1):239-248; doi:10.1093/carcin/bgh298
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/1/239    most recent
bgh298v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Loeppen, S.
Right arrow Articles by Schwarz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loeppen, S.
Right arrow Articles by Schwarz, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis vol.26 no.1 © Oxford University Press 2005; all rights reserved.

ARTICLE

A ß-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors

Sandra Loeppen, Christoph Koehle, Albrecht Buchmann and Michael Schwarz1

Department of Toxicology, Institute of Pharmacology and Toxicology, University of Tuebingen, Wilhelmstrasse 56, 72074 Tuebingen, Germany

1 To whom correspondence should be addressed Email: michael.schwarz{at}uni-tuebingen.de

Phenobarbital (PB) is a model tumor promoter in the rodent liver. In the mouse, the promotional effect of PB results from a selective stimulation of clonal outgrowth of hepatocytes harboring activating mutations in the ß-catenin (catnb) gene. Glutamine synthetase (GS), a downstream target in the Wnt/ß-catenin/T-cell factor (TCF) signaling pathway, is strongly up-regulated in catnb-mutated mouse liver tumors and may serve as a marker for their identification. Here we show that the levels of several cytochrome P450 (CYP) isoenzymes are also altered in GS-positive liver tumors. Immunohistochemical and western blotting analyses demonstrated that GS-positive, catnb-mutated tumors showed levels of CYP1A, CYP2B, CYP2C and CYP2E1, which were similar or slightly enhanced in comparison with non-tumoral liver tissue. This contrasts with tumors without catnb mutations, which exhibited decreased levels of these CYP isoforms. Real-time RT–PCR revealed that the differences in CYP levels in the tumors corresponded to changes in the respective mRNAs. Mouse hepatoma cells were transiently transfected with an expression vector encoding an S33Y-mutated ß-catenin protein, which was functional with regard to transactivation of a ß-catenin/TCF-responsive (topflash) reporter construct. Co-transfected with luciferase reporter vectors containing either the regulatory upstream sequence of the CYP2B1 gene or three dioxin-responsive core elements were activated by S33Y-ß-catenin. These results indicate that mutation of catnb leads to transcriptional activation of CYP isoenzymes in mouse liver tumors. As CYPs are involved in both the activation and the inactivation of several clinically important anticancer drugs, our findings may be relevant for chemotherapy of human cancers, where activation of ß-catenin-dependent signaling by mutation of the gene or alternative mechanisms is frequently observed.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
A. Braeuning, R. Sanna, J. Huelsken, and M. Schwarz
Inducibility of Drug-Metabolizing Enzymes by Xenobiotics in Mice with Liver-Specific Knockout of Ctnnb1
Drug Metab. Dispos., May 1, 2009; 37(5): 1138 - 1145.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
P. Marx-Stoelting, J. Mahr, T. Knorpp, S. Schreiber, M. F. Templin, T. Ott, A. Buchmann, and M. Schwarz
Tumor Promotion in Liver of Mice with a Conditional Cx26 Knockout
Toxicol. Sci., June 1, 2008; 103(2): 260 - 267.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. Bulckaen, G. Prevost, E. Boulanger, G. Robitaille, V. Roquet, C. Gaxatte, G. Garcon, B. Corman, P. Gosset, P. Shirali, et al.
Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging
Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1562 - H1570.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. Braeuning, C. Ittrich, C. Kohle, A. Buchmann, and M. Schwarz
Zonal Gene Expression in Mouse Liver Resembles Expression Patterns of Ha-ras and {beta}-Catenin Mutated Hepatomas
Drug Metab. Dispos., April 1, 2007; 35(4): 503 - 507.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C.-A. Renard, C. Labalette, C. Armengol, D. Cougot, Y. Wei, S. Cairo, P. Pineau, C. Neuveut, A. de Reynies, A. Dejean, et al.
Tbx3 Is a Downstream Target of the Wnt/{beta}-Catenin Pathway and a Critical Mediator of {beta}-Catenin Survival Functions in Liver Cancer
Cancer Res., February 1, 2007; 67(3): 901 - 910.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
J. Strathmann, M. Schwarz, J. C. Tharappel, H. P. Glauert, B. T. Spear, L. W. Robertson, K. E. Appel, and A. Buchmann
PCB 153, a Non-dioxin-like Tumor Promoter, Selects for {beta}-Catenin (Catnb)-Mutated Mouse Liver Tumors
Toxicol. Sci., September 1, 2006; 93(1): 34 - 40.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.